← All trials
NCT02505750
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2015
- Primary completion
- Mar 1, 2021
- Completion date
- Mar 1, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 236
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Nice Sophia AntipolisLead sponsor
- Institut Paoli-CalmettesCollaborator
- Centre Leon BerardCollaborator
- University of LyonCollaborator
- University of LiverpoolCollaborator
- University of NottinghamCollaborator
- University of LondonCollaborator
- Centre de Haute EnergieCollaborator
- Clinique CharcotCollaborator
- Uppsala UniversityCollaborator
- University of HullCollaborator
- Aarhus UniversityCollaborator
- Karolinska InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.